An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor–sensitizing and T790M resistance mutations. Almost all patients who initially respond to an epidermal growth factor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Med Case Rep
Main Authors: Miyazaki, Shinichi, Kuno, Yasumasa, Hayai, Shunsaku, Teramachi, Ryo, Yamashita, Ryo, Saito, Yusuke, Higuchi, Kosuke, Nara, Yoshiharu, Ikeda, Takuya
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7412784/
https://ncbi.nlm.nih.gov/pubmed/32762742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13256-020-02447-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados